A Data-Driven Approach to Predicting Specialty Pharmacy Costs

via Lockton Benefits Insight & Guidance

Hundreds of new specialty drugs are in the approval pipeline. Because these new drugs come with high price tags, the time to begin predicting their impact on your plan’s costs is now, before they hit the market. What kinds of drugs are we talking about?

Here are two examples:

  • A cystic fibrosis drug is anticipated for release later this year, and it comes with a price tag of $300,000 per patient, annually.
  • New drugs for treating Fabry disease and Wolman disease could cost more than $400,000 per year, each.

To read the full article CLICK HERE

Advertisements

About thebenefitblog

Eric is a Producer at Lockton Insurance Brokers, Inc., the world’s largest privately held commercial broker. Eric has over 23 years of experience in the insurance industry and has spent the last 11 years with Lockton. Eric specializes in Health & Welfare Benefits, Retirement Planning, and Executive Benefits. Eric's clients utilize his expertise in the areas of Plan Due Diligence, Transaction Structure, Fiduciary Oversight, Investment Design, Compliance and Vendor negotiation to improve the operational & financial outcome for each client. The Benefit Blog is a place to share that expertise and industry news.
This entry was posted in Uncategorized. Bookmark the permalink.